Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenyuan is a Traditional Chinese Medicine (TCM) formula developed by the Hubei Provincial Hospital of Traditional Chinese Medicine, specifically indicated for the treatment of diabetic kidney disease (DKD). It is typically administered as an oral granule (Shenyuan Granules) or capsule. The formulation is based on the TCM therapeutic principles of Jian-Pi Bu-Shen (invigorating the spleen and tonifying the kidney) and Qu-Yu Tong-Luo (eliminating blood stasis and activating collaterals). Clinical research, including trials registered under ChiCTR2000030596, evaluates its efficacy in reducing proteinuria and improving renal function in patients with diabetic nephropathy. As a hospital-made preparation (院内制剂), it is primarily utilized within the clinical practice of its developing institution.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shenyuan.